A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Iovance Biotherapeutics, Inc. IOVA

Mixed broader-coverage candidate · Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions.

On FrontierLab's discovery record since 2026-06-24 (8 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-07), not the curated Frontier signal.

⚡ Surfaced on a price move — momentum is where to look, not a buy signal. The move that surfaced this name does not make it a good entry.

⚠ Pump risk: parabolic/spike characteristics detected in the screen flags. Treat any positive grade with extra skepticism.

Key quality signals

Revenue growth (YoY)	34.5%
Gross margin	116.3%
Gross profits / assets	0.41
Rule of 40	-58.2
Net margin	-92.7%
Cash runway (months)	13.5
PEG	—
Price / sales	8.5

Quality checklist

✓ Revenue growth — 34.5% (pass ≥ 20%)
✓ Gross profits / assets — 0.41 (pass ≥ 0.33)
✓ Gross margin — 116.3% (pass ≥ 60%)
~ Cash generation
✗ Share dilution — 34.6%

Fundamentals — snapshot as of 2026-08-07

Stage	Established
Share issuance (YoY)	34.6% · heavy issuance
Moat	—
TAM	—
P/E (trailing)	—
EPS (trailing)	$-0.70
Burn multiple	0.8
Gross-margin trend (pts)	95.7
Cash / assets	0.33
Net debt / EBITDA	—
Statements as of	Q2 FY2026 · filed 2026-08-06

Momentum context — a snapshot from 2026-08-07, not current

Price at surface	$6.21 (as of 2026-08-07)
52-week range	$1.76 – $6.39
% off 52-wk high	-2.8%
RSI (14)	70
Relative volume	3.8×

Risk flags

Burning cash — operating margin is negative.Heavy dilution (~35%/yr) — top-decile share issuers have historically underperformed.Parabolic one-day spike (+43%) in the last month — extreme single-day moves tend to mean-revert.Volume 3.8× normal alongside the move — attention-crowded names tend to reverse over the following weeks.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-08-07 (end-of-day). How grades are computed →